

ACAA, wherein each A and C is as independently defined in claim 1;

Gly<sub>p</sub>, wherein p is an integer of from 0 to 10; and

Ala<sub>q</sub>, wherein q is an integer of from 0 to 10.

*C1*  
*Sub F1*  
5. (Amended) The purified peptide according to claim 1, wherein R<sup>1</sup>-R<sup>2</sup> or R<sup>3</sup>, or

both, do not comprise an amino acid selected from the group consisting of A, B and C as defined in claim 1.

6. (Amended) The purified peptide according to claim 1, wherein motifs (A-C-B-A)

are present in said peptide in a greater amount than motifs (A-B-C-A).

*C2*  
*Sub D5*  
8. (Twice amended) The peptide BP 1, having SEQ ID NO: 1.

9. (Twice amended) The peptide BP 2, having SEQ ID NO: 2.

10. (Twice amended) The peptide BP 2.3, having SEQ ID NO: 3.

11. (Twice amended) The peptide BP 2.4, having SEQ ID NO: 4.

12. (Twice amended) The peptide BP 2.5, having SEQ ID NO: 5.

*Sub F1*  
13. (Twice Amended) The purified peptide according to claim 1, wherein the peptide

is coupled to a non-peptide carrier, radioactive tag or fluorescent label.

*C3*  
14. (Amended) A fusion peptide comprising the peptide of claim 1 coupled to a second peptide selected from the group consisting of peptide carriers and diagnostic peptides.

*Sub D6*  
15. (Amended) A pharmaceutical composition comprising a peptide according to claim 1 as active component for treating topical and systemic microbial or parasite infection, or both, and a pharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.



wherein

$R^1$ ,  $R^2$ , and  $R^3$  each are an amino acid,

$x$  is an integer  $\geq 0$ ,

$y$  is an integer  $\geq 0$ ,

each  $A$  is an amino acid independently selected from the group consisting of Lys, Arg and His,

each  $B$  is an amino acid independently selected from the group consisting of Phe, Trp and Tyr,

each  $C$  is an amino acid independently selected from the group consisting of Leu, Ile, Val and Ala,

$m$  is an integer of from 2 to 8,

$n$  is an integer of from 1 to 3, and

wherein one or more of the sequence motifs  $(A-B-C-A)$  may have the retro orientation  
(A-C-B-A).

2. (Amended) The purified peptide according to claim 1, wherein  $x$  and  $y$  are each an integer of from 0 to 15.

*3.* (Amended) The purified peptide according to claim 1, wherein  $x$  and  $y$  are each an integer of from 1 to 10.

*4.* (Amended) The purified peptide according to claim 1, wherein  $R^1$  is selected from the group consisting of:

*Sub F1*  
21. (Amended) A pharmaceutical composition comprising a mixture of at least two peptides according to claim 1 as active components for treating topical and systemic microbial or parasite infections, or both, and a pharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.

*C4*  
22. (Amended) The pharmaceutical composition according to claim 15, further comprising an antibiotic selected from the group consisting of penicillins, cephalosporins,  $\beta$ -lactams, aminoglycosides, quinolones, tetracyclines, macrolides, glycopeptides or lipopeptides, hydrophobic antibiotics, ribosome inhibitors or antibiotics having a large lipid-like lactone ring.

*21 23.* (Amended) The pharmaceutical composition according to claim 15, wherein the infection is caused by a parasite.

*Sub F1*  
*C5*  
28. (Amended) A method for treatment of microbial infection in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a peptide according to claim 1.

*25 29.* (Amended) The method according to claim 28, wherein said treatment is applied after trauma or suspected infection has occurred.

Please add the following new claims:

*Sub F1*  
40. A pharmaceutical composition for treating bacterial inflammation comprising a therapeutically effective amount of a purified peptide according to claim 1, and a pharmaceutically acceptable carrier.

41. A pharmaceutical composition for treating bacterial septic shock comprising a therapeutically effective amount of a peptide according to claim 1, and a pharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.

*Sub F1* 29 42. The purified peptide according to claim 1, wherein x and y are each 0.

43. The pharmaceutical composition according to claim 28, wherein said parasite is selected from the group consisting of a parasite causing malaria and a parasite causing Trypanosomiasis.

*C 6* 44. A method for treatment of microbial infection in a human, comprising administering to a human in need of such treatment a therapeutically effective amount of a peptide according to claim 1.

*Sub F1* 45. A method for inhibiting the growth of a microbe comprising the step of contacting a microbe with an effective amount of a purified peptide according to claim 1.

46. A method for inhibiting the growth of a Gram-negative bacterium comprising the step of contacting a Gram-negative bacterium with an effective amount of a purified peptide according to claim 1.

47. A method for inhibiting the growth of a Gram-positive bacterium comprising the step of contacting a Gram-positive bacterium with an effective amount of a purified peptide according to claim 1.